• In late July 2026, Pfizer reported positive Phase 3 results for its oral JAK3/TEC inhibitor LITFULO in nonsegmental vitiligo and secured European Commission approval for its 2026–2027 XFG‑adapted COVID-19 vaccine for individuals six months and older.
• Together, these milestones highlight Pfizer’s push to build a broader immunology and dermatology franchise while maintaining a recurring role in seasonal COVID-19 vaccination campaigns.
• With this backdrop, we’ll now examine how LITFULO’s Phase 3 success in vitiligo could reshape Pfizer’s longer-term investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Pfizer Investment Narrative Recap

To own Pfizer today, you need to believe its broad pipeline and large existing franchises can offset pressure from drug pricing reforms, patent expirations, and softer COVID revenue. The LITFULO vitiligo data and XFG adapted COVID vaccine approval both support that pipeline story, but they do not change the near term focus on execution around upcoming launches, cost controls, and the risk that revenue and earnings may continue to trend lower.

Among recent updates, the FDA’s Priority Review of TALZENNA plus XTANDI in metastatic castration sensitive prostate cancer stands out. This oncology combination directly relates to Pfizer’s efforts to ease the patent cliff risk around big cancer drugs and shows how label expansions could help sustain key franchises, even as the company works to build new revenue streams in immunology and dermatology alongside LITFULO.

Yet, against this progress, investors should be aware that the biggest medium term threat could still come from...

Pfizer's narrative projects $54.9 billion revenue and $9.2 billion earnings by 2029.

Uncover how Pfizer's forecasts yield a $29.19 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimating analysts were assuming Pfizer’s revenue could fall to about US$50.9 billion and earnings to roughly US$6.0 billion by 2029, which is far more pessimistic than consensus and may look different once you weigh that view against LITFULO’s Phase 3 success and the possibility that late stage oncology programs actually deliver.

Explore 21 other fair value estimates on Pfizer - why the stock might be worth just $24.00!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pfizer research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Pfizer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pfizer's overall financial health at a glance.

No Opportunity In Pfizer?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Find 57 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.